Miscellaneous

Bio's National Investor Conference Plays Matchmaker

Wednesday, April 23, 2008 12:21 PM

CenterWatch ‘watched’ as more than 60 emerging biotech companies and 125 venture capitalists from across the U.S. converged at the 1st annual BIO National Venture Conference in Boston this week.

More... »

CWWeekly April 14th 2008 Issue

Saturday, April 19, 2008 12:07 PM

Top News

More... »

Magic Johnson—Celebrity Spokesperson for Minority Patient Recruitment?

Friday, April 18, 2008 12:18 PM

Earvin “Magic” Johnson, NBA champion and chairman and chief executive officer of the Johnson Development Corp., came to IIR’s 17th Annual Partnerships with CROs in Las Vegas, Nevada, with a mission—to urge pharma to increase minority participation in clinical trials. But, he left, quite possibly, with an even bigger mission—to become a celebrity spokesperson for minority patient recruitment.

More... »

CenterWatch Monthly April 2008 Issue

Thursday, April 17, 2008 04:14 PM

FDA Debarment Failures a Wake-Up Call for CROs, Drug Sponsors

More... »

Coast IRB Receives FDA Warning Letter

Tuesday, April 15, 2008 11:42 AM

Coast IRB, an independent institutional review board (IRB) based in Colorado Springs, Colo., received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning the company’s improper expedited review of a phase I study being conducted in northern California. In an unusual move, the agency has temporarily suspended the IRB’s ability to do expedited reviews.

More... »

CWWeekly April 7th 2008 Issue

Friday, April 11, 2008 05:12 PM

Top News

More... »

Suven Teams up With Chinese CRO VPSCRO

Friday, April 11, 2008 12:54 PM

Asian Clinical Trials (ACT), the CRO of Hyderabad, India-based pharmaceutical company Suven Life Sciences, has entered into a pact with the Beijing -based company VPSCRO to conduct clinical trial services in India and China. VPSCRO claims it is the largest Chinese CRO in term of numbers of ongoing trials. The companies stated that the agreement will provide cost-effective services with faster patient recruitment speeds in the two regions.

More... »

Parexel's Josef von Rickenbach On Phase I Activity

Tuesday, April 8, 2008 06:16 AM

Parexel recently expanded its early phase operations in three of its phase I facilities. The move brings the company’s global phase I bed capacity to one of the largest in the industry, at 550.

Parexel also has phase I services in India through a partially owned venture with Synchron Clinical Research’s Ahmedabad-based facility, which has 86 beds. Last month, Parexel increased its ownership stake in that venture from 19.5% to 31% at a cost of $5 million. At the same time, Parexel sold its France-based bioanalytical and biomarker testing laboratory facility—owned since 1999—to a subsidiary of Synchron for approximately $6.7 million. The unit will now be called Synexel Research International and will stay within Synchron’s operational network.

More... »

U.S. Disease Foundation Investment in Biopharmaceutical Industry Continues to Rise

Monday, April 7, 2008 02:47 PM

U.S. disease foundations invested about $75 million last year in biopharmaceutical companies to fund discovery and development of new drugs and therapies for their corresponding diseases, according to CenterWatch estimates published in the August 2007 issue of The CenterWatch Monthly.

More... »

EDICT Report Provides Road Map To Comprehensive Patient Enrollment

Monday, April 7, 2008 06:01 AM

A much anticipated report published by Baylor College’s Eliminating Disparities in Clinical Trials [EDICT] project has provided a nine-step action plan for improving the policies surrounding the conduct of clinical trials. The EDICT project set out to create a series of policy proposals designed to help patient recruitment and retention in clinical trials. The four-year project is supported by an unrestricted grant from Genentech.

More... »